Evercore ISI initiates Lycia stock with outperform rating
Evercore ISI initiated coverage on Lycia Therapeutics (NASDAQ:LYCA) with an outperform rating and a $43 price target, citing its LYTACs technology. The company's lead program targets IgE, with clinical trials for food allergies and Graves disease. Lycia raised $318 million in its IPO, priced at $18 per share. Jefferies and TD Cowen also initiated coverage with buy ratings and price targets of $50 and unspecified, respectively.
How this was made
The 30-second read
Why it matters
The new analyst initiation provides a fresh valuation anchor and highlights near-term scientific checkpoints (PK/PD measures expected next year) that can influence trading around biotech risk appetite.
Market read
Traders may adjust LYCA positioning based on the new rating/target, while monitoring the next-year PK/PD readouts and the 2028 Phase 2b start as the next fundamental inflection points.
What to watch
The piece also notes the stock may be overvalued versus fair value and that the company is still unprofitable, which can cap follow-through if risk appetite fades.
Background
Lycia Therapeutics is a clinical-stage biotech developing LYTACs, including an IgE degrader for food allergy and a Graves disease program targeting TSH receptor antibodies.
Ticker impact
Evercore ISI initiated coverage on Lycia Therapeutics with an Outperform rating and a $43 price target, citing its LYTAC IgE and Graves programs.
Likely upward bias as traders price in the initiation target, tempered by the clinical-stage timeline and unprofitability.
The article provides a fresh, attributable catalyst (new coverage and target) plus specific development milestones (PK/PD next year, Phase 2b start in 2028), which shape risk/reward expectations.
Market effects
Reinforces positive sentiment toward extracellular targeted protein degradation (LYTACs) and immunology-focused biotech platforms.
Limited, primarily affects US small/mid-cap biotech sentiment rather than broad regional flows.
Low; the catalyst is company-specific analyst initiation and does not indicate a global macro or cross-market shock.
Counterpoint
The article’s upside case is valuation-driven and heavily dependent on future clinical milestones, so the initiation may not change fundamentals until PK/PD and Phase 2b progress.
Key entities
- companyLycia Therapeutics
NASDAQ-listed clinical-stage biotech developing LYTACs for IgE-mediated food allergy and Graves disease.
- analyst_firmEvercore ISI
Initiated coverage with an Outperform rating and a $43 price target.
